Published Date: 25 Jul 2025
The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients.
Read Full NewsThird molar removal may improve oral health markers, but its benefits must be weighed against surgical risks, postoperative morbidity, and cost.
Stopping aspirin early in dual antiplatelet therapy is tied to a lower risk for bleeding with no increase in ischemic risks after coronary stenting, a new meta-analysis finds.
The World Health Organization on Thursday declared the hantavirus outbreak linked to a cruise ship over after the last identified contact of an exposed person completed...
New South Wales became Australia's third state to confirm a case of H5N1 bird flu after authorities said a migratory seabird found near a coastal town returned a positive...
The $500 million seed fund will support universal antiviral platforms and air cleaning technologies.
New study finds nearly 10% of internal medicine residents report a disability; the American Medical Association updates maternity care billing codes; and Texas joins autism trial network.
A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL.
1.
Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.
2.
Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.
3.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
4.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
5.
Genetics and therapy type determine second cancer risk after childhood treatment, study finds
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
3.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
4.
Tumor Microenvironment Reprogramming in Cancer Treatment
5.
Building Bridges between Heart and Cancer Care: A Comprehensive Guide to Cardio-Oncology Clinics
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation